

### A FIRST-IN-HUMAN PHASE 1/2 OPEN LABEL TRIAL EVALUATING THE SAFETY, PHARMACOLOGY, AND PRELIMINARY EFFICACY OF VT1021 IN SUBJECTS WITH ADVANCED SOLID TUMORS

<sup>1</sup>Devalingam Mahalingam\*, <sup>2</sup>Wael Harb, <sup>3</sup>Amita Patnaik, <sup>4</sup>Susanna Ulahannan, <sup>5</sup>Haider Mahdi, <sup>6</sup>Manmeet Ahluwalia, <sup>6</sup>Manish Patel, <sup>7</sup>Afshin Dowlati, <sup>8</sup>Andrea Bullock, <sup>9</sup>Patrick Wen, <sup>10</sup>Shubham Pant, <sup>1</sup>Mary Mulcahy, <sup>11</sup>Robert Guttendorf, <sup>12</sup>Lou Vaickus, <sup>13</sup>Suming Wang, <sup>13</sup>Marsha Crochiere, <sup>13</sup>Melanie Vincent, <sup>13</sup>Michael Cieslewicz, <sup>13</sup>Jing Watnick. <sup>1</sup>Northwestern University Medical School, Chicago, IL, USA; <sup>2</sup>Horizon Oncology Center, Lafayette, IN, USA; <sup>3</sup>South Texas Accelerated Research Therape, San Antonio, TX, USA; <sup>4</sup>University of Oklahoma Health Sciences C, OKC, OK, USA; <sup>5</sup>Cleveland Clinic, Cleveland, OH, USA; <sup>6</sup>Florida Cancer Specialists, Sarasota, FL, USA; <sup>7</sup>Case Western, Cleveland, OH, USA; <sup>8</sup>Beth Israel Deaconess Hospital, Boston, MA, USA; <sup>9</sup>Dana Farber Cancer Institute, Boston, MA, USA; <sup>10</sup>MD Anderson, Houston, TX, USA; <sup>11</sup>Acclairo Pharmaceutical Development Group, Vienna, VA, USA; <sup>12</sup>aktaPD/Vigeo Therapeutics, Boston/Cambridge, MA, USA; <sup>13</sup>Vigeo Therapeutics, Cambridge, MA, USA

**Background** VT1021, a cyclic pentapeptide, reprograms myeloid-derived suppressor cells (MDSCs) and induces the production of thrombospondin-1 (Tsp-1) in the tumor microenvironment (TME). Tsp-1, via binding to CD36 and CD47, induces apoptosis in tumor and endothelial cells, blocks the ‘do-not-eat-me’ signal, increases the M1:M2 macrophage ratio and activates cytotoxic T lymphocytes (CTLs). Preclinical studies showed robust anti-tumor activities of VT1021 in multiple animal models.

**Methods** This is a first-in-human, Ph 1/2, open-label, multicenter dose escalation and expansion study in advanced solid tumors. The primary objectives are to determine the recommended Phase 2 dose (RP2D) and characterize the safety and tolerability of VT1021. Secondary objectives are to characterize the adverse event (AE) profile, evaluate pharmacokinetics (PK), and describe preliminary efficacy. Exploratory objectives include evaluation of pharmacodynamic effects of VT1021 in tumor, TME, and peripheral blood. The expansion phase focuses on ovarian, pancreatic, triple negative breast cancer, glioblastoma, and a basket cohort with high CD36-expressing tumors.

**Results** In the escalation phase, 46 subjects received between 0.5–15.6 mg/kg of VT1021 by IV infusion twice weekly. VT1021 has been well tolerated through all doses tested. One patient dosed at 1.0 mg/kg developed a grade 3 infusion reaction and 3 patients dosed at 1.0, 6.6, and 8.8 mg/kg respectively developed grade 2 infusion reactions. Other drug related AEs included grade 1–2 fatigue (n=7), nausea (n=4), constipation (n=2), increased aspartate aminotransferase (n=2) and blood bilirubin (n=2), hypomagnesaemia (n=2), and dizziness (n=2). Dose proportionality was observed in PK analysis. Among 28 evaluable subjects, one partial response (thymoma, 372+ days on treatment) and 11 stable disease (SD) in 9 different solid tumors have been observed for a disease control rate of 43%. Seven of eleven SDs had high CD36 AND high CD47 expression with an average duration of 162 days on study. VT1021 induced Tsp-1 production in peripheral blood cells at most dose levels. In addition, on-study biopsies exhibited increased Tsp-1 expression in the TME by activation of p53 in MDSCs, increased CTL infiltration, increased M1:M2 macrophage ratio, and reduced regulatory T cells in the TME. The RP2D was declared to be 11.8 mg/kg and enrollment in tumor-specific expansions is on-going.

**Conclusions** Through all doses tested, VT1021 was safe and well tolerated, with dose proportional PK properties. In addition, VT1021 has demonstrated activities in reprogramming the TME which resulted in a high disease control rate in subjects with tumors expressing both high CD36 and high CD47.

Trial Registration NCT03364400

**Ethics Approval** The study was approved by Northwestern University Medical School institutional review board (IRB), approval number 00000418, Horizon Oncology Center IRB, approval number 00001313, South Texas Accelerated Research Therapeutic IRB, approval number 00003657, University of Oklahoma Health Sciences Center IRB, approval number 00006075, Cleveland Clinic IRB, approval number 00000536, Florida Cancer Specialists IRB, approval number 00006075, Case Western IRB, approval number 00000536, Beth Israel Deaconess Hospital and Dana Farber Cancer Institute IRB, approval number 00000753 and MD Anderson IRB, approval number 00006023.

<http://dx.doi.org/10.1136/jitc-2020-SITC2020.0374>

### EXPANSION OF HPV-16 SPECIFIC T CELLS IN PATIENTS WITH HPV-RELATED CANCERS TREATED WITH BINTRAFUSP ALFA

Nicole Toney\*, Yo-Ting Tsai, Claire Rumfield, Samuel Pellom, Caroline Jochems, Julius Strauss, James Gulley, Jeffrey Schlom, Renee Donahue. *NIH, Bethesda, MD, USA*

**Background** The safety and efficacy of bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the TGF-βRII receptor (a TGF-β ‘trap’) fused to a human IgG1 mAb blocking PD-L1, have been demonstrated in patients with human papillomavirus (HPV)-related cancers in an open label, multicenter phase 1 trial (NCT02517398), and an open-label, single center phase 2 trial (NCT03427411). The current study aimed to investigate whether HPV-16-specific T cells are expanded with therapy and associate with the clinical response of patients in these trials. We also present pre-clinical evidence from a mouse model of HPV-associated cancer supporting the combination of bintrafusp alfa with an HPV-16 targeted therapeutic vaccine and an immunostimulatory cytokine.

**Methods** Peripheral blood mononuclear cells (PBMC) were obtained from 33 patients prior to and 2 weeks after 1 and/or 3 cycles of bintrafusp alfa and evaluated for HPV-16 specific CD4+ and CD8+ T cells. PBMCs were stimulated with 15-mer peptide pools of the HPV-16 E6 and E7 oncoproteins, and T cell responses were assessed for the production of cytokines (TNFα, IFNγ, IL-2) and positivity for the degranulation marker CD107a. Multifunctional T cells, positive for >2 measures, were also enumerated. For pre-clinical studies, a syngeneic mouse model of TC-1 carcinoma was treated with bintrafusp alfa alone or in combination with a liposomal-based HPV-16 therapeutic vaccine (PDS 0101) and a tumor targeting immunocytokine (NHS-muIL12) and evaluated for anti-tumor activity and immune responses.

**Results** HPV-16 specific T cells were increased after 1 cycle of bintrafusp alfa in a greater proportion of responders (9/14) than non-responders (4/17) (p=0.03). In addition, the magnitude of HPV-16 specific T cells was greater after 1 (p=0.04) and 3 (p<0.0001) cycles of bintrafusp alfa in responders than non-responders. Multifunctional HPV-16-specific T cells were also increased to a greater extent in responders than non-responders. Preclinical studies demonstrated that the combination of bintrafusp alfa with an HPV-16-targeted therapeutic vaccine along with an immunocytokine resulted in maximal anti-tumor activity and T cell responses.